Aromatase inhibitors in advanced breast cancer

Seminars in Oncology

Volumn 31, Issue SUPPL. 12, 2004, Pages 3-8

  Mouridsen, Henning T ^a,b  

^a Rigshospitalet   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; EXEMESTANE; FULVESTRANT; GESTAGEN; LETROZOLE; TAMOXIFEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; NITRILE; TRIAZOLE DERIVATIVE;

ALOPECIA; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ESTROGEN ACTIVITY; FOLLOW UP; HORMONAL THERAPY; HORMONE SENSITIVITY; HOT FLUSH; HUMAN; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; VAGINAL DRYNESS; WEIGHT GAIN; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; FEMALE; METASTASIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; NITRILES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; TRIAZOLES;

EID: 18144363949     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.09.020     Document Type: Article

References (32)

1. H. Mouridsen, M. Gershanovich, Y. Sun Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer Results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 19 2001 2596 2606
2. S.S. Legha Tamoxifen in the treatment of breast cancer Ann Intern Med 109 1988 219 228
3. R.J. Santen, A. Manni, H. Harvey Endocrine treatment of breast cancer in women Endocr Rev 11 1990 221 265
4. M. Castiglione-Gertsch, S. Pampallona, M. Varini Primary endocrine therapy for advanced breast cancer To start with tamoxifen or with medroxyprogesterone acetate? Ann Oncol 4 1993 735 740
5. K.E. Gale, J.W. Andersen, D.C. Tormey Hormonal treatment for metastatic breast cancer An Eastern Cooperative Oncology Group phase III trial comparing aminoglutethimide to tamoxifen Cancer 73 1994 354 361
6. H.B. Muss, L.D. Case, J.N. Atkins Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer A Piedmont Oncology Association study J Clin Oncol 12 1994 1630 1638
7. H.T. Mouridsen, C. Rose, A.H. Brodie Challenges in the endocrine management of breast cancer Breast 12 suppl 2 2003 S2 S19
8. H. Mouridsen, M. Gershanovich, Y. Sun Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 2003 2101 2109
9. J. Bonneterre, A. Buzdar, J.M. Nabholtz Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Results of two randomized trials designed for combined analysis Cancer 92 2001 2247 2258
10. R. Paridaens, P. Therasse, L. Dirix First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) - EORTC 10951 in collaboration with Exemestane Working Group and NCIC Eur J Cancer Suppl 2 2004 126 (abstr 241)
11. R.J. Santen, H.A. Harvey Use of aromatase inhibitors in breast carcinoma Endocr Relat Cancer 6 1999 75 92
12. R.J. Santen Clinical review 149: To block estrogen's synthesis or action: that is the question J Clin Endocrinol Metab 87 2002 3007 3012
13. P.E. Lønning The role of aromatase inactivators in the treatment of breast cancer Int J Clin Oncol 7 2002 265 270
14. J.A. Ligibel, E.P. Winer Clinical differences among the aromatase inhibitors Clin Cancer Res 9 suppl 2003 473s 479s
15. R. Paridaens, L. Dirix, C. Lohrisch Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer Ann Oncol 14 2003 1391 1398
16. A.U. Buzdar Role of aromatase inhibitors in advanced breast cancer Endocr Relat Cancer 6 1999 219 225
17. W.R. Miller, J.M. Dixon Local endocrine effects of aromatase inhibitors within the breast J Steroid Biochem Mol Biol 79 2001 93 102
18. J. Geisler, B. Haynes, G. Anker Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study J Clin Oncol 20 2002 751 757
19. A.U. Buzdar Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer Oncologist 8 2003 335 341
20. C. Rose A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer Am J Clin Oncol 26 2003 S9 S16
21. H.T. Mouridsen, H.A. Chaudri-Ross Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women Survival analysis and updated safety results" by J.-M. Nabholtz et al Eur J Cancer 40 2004 1095 1096
22. J.-M. Nabholtz Reply to comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women survival analysis and updated safety results" by H.T. Mouridsen, H.A. Chaudri-Ross Eur J Cancer 40 2004 1097
23. J. Bonneterre, B. Thürlimann, J.F.R. Robertson Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study J Clin Oncol 18 2000 3748 3757
24. J.M. Nabholtz, A. Buzdar, M. Pollak Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women Results of a North American multicenter randomized trial J Clin Oncol 18 2000 3758 3767
25. J.-M. Nabholtz, J. Bonneterre, A. Buzdar Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women Survival analysis and updated safety results Eur J Cancer 39 2003 1684 1689
26. P. Dombernowsky, I. Smith, G. Falkson Letrozole, a new oral aromatase inhibitor for advanced breast cancer Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate J Clin Oncol 16 1998 453 461
27. A. Buzdar, J. Douma, N. Davidson Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate J Clin Oncol 19 2001 3357 3366
28. M. Kaufmann, E. Bajetta, L.Y. Dirix Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer Results of a phase III randomized double-blind trial J Clin Oncol 18 2000 1399 1411
29. M. Gershanovich, H.A. Chaudri, D. Campos Letrozole, a new oral aromatase inhibitor Randomized trial comparing 2.5 mg daily, 0.5 mg daily, and aminoglutethimide in postmenopausal women with advanced breast cancer Ann Oncol 9 1998 639 645
30. C.K. Osborne, J. Pippen, S.E. Jones Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy Results of a North American trial J Clin Oncol 20 2002 3386 3395
31. P.E. Lønning, E. Bajetta, R. Murray Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors A phase II trial J Clin Oncol 18 2000 2234 2244
32. P.E. Lønning Pharmacology and clinical experience with exemestane Exp Opin Invest Drugs 9 2000 1897 1905